Wuxi Biologics Ireland Limited

Qin Mei

Jing Li

Zhuozhi Wang

Jianqing Xu

Jieying Liu

Fagen Hu

Yuhong Shen

Jiaxiang Shao

Provided are anti-CD47 antibodies, the nucleic acid molecules encoding the anti-CD47 antibodies, expression vectors and host cells used for the expression of anti-CD47 antibodies. Provided are methods for validating the function of antibodies. The antibodies provide a potent agent for the treatment of cancers via modulating immune functions.

Anti-CD47 antibodies and uses thereof

The present disclosure provides isolated monoclonal anti-CD3epsilon antibodies or antigen-binding fragments thereof comprising one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 47, and/or one or more kappa light chain CDR sequences selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the use thereof.

Anti-CD3epsilon antibodies

A bispecific anti-CD3&#xd7;CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3&#xd7;CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3&#xd7;CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3&#xd7;CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3&#xd7;CD19 polypeptide complex are provided.

Bispecific CD3/CD19 polypeptide complexes

Growing community of inventors

Shanghai, China

Qin Mei